We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | 장 마감 후 (AMC) | $1.1 | — | — | $329.7M | — | 예정 |
| FY2026 Q3 | 2024. 12. 28. | 시각 미정 | — | $2.14 | — | — | $1.03B | 보고됨 |
| FY2026 Q2 | 2024. 09. 28. | 시각 미정 | — | $1.4 | — | — | $681.68M |
Consensus PT $81.6 · 10 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 29. | Citigroup | — | 의견 유지 | Neutral → Neutral | — | Citigroup: Neutral |
| 2026. 05. 22. | B of A Securities | — | 투자의견 상향 | Neutral → Buy | — | B of A Securities: Neutral → Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2026 Q1 | 2024. 06. 29. | 시각 미정 | — | $0.74 | — | — | $336.17M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
Stored first · Google News · Yahoo Finance (English)
Haemonetics Corp stock (US4041191090): shares trade lower after recent pullback on NYSE - AD HOC NEWS
Haemonetics Corp stock (US4041191090): shares trade lower after recent pullback on NYSE AD HOC NEWS
Haemonetics upgraded at BofA on conservative outlook - MSN
Haemonetics upgraded at BofA on conservative outlook MSN
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Raises Target Price to $70 - 富途牛牛
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Raises Target Price to $70 富途牛牛
John Slump Launches Metis MedTech Following Atraverse Medical Acquisition by Johnson & Johnson
Why Haemonetics NYSE Composite Earnings Sparked Attention? - Kalkine Media
Why Haemonetics NYSE Composite Earnings Sparked Attention? Kalkine Media
Haemonetics' (NYSE:HAE) Conservative Accounting Might Explain Soft Earnings - simplywall.st
Haemonetics' (NYSE:HAE) Conservative Accounting Might Explain Soft Earnings simplywall.st